Holocene Advisors
MDCO

Holocene Advisors’s Medicines Co MDCO Stock Holding History

Holocene Advisors’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-176,515
Closed -$8.83M – 812
2019
Q3 		$8.83M Buy
+176,515
New +$7.04M 0.09% 135
2018
Q1 		– Sell
-16,768
Closed -$458K – 791
2017
Q4 		$458K Buy
+16,768
New +$516K 0.01% 437

Other funds holding MDCO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Holocene Advisors's MDCO Position: Q4 2019 in Review

Holocene Advisors sold out of Medicines Co (MDCO) in Q4 2019, closing a stake of 176,515 shares — an estimated $8.83M sold.

Holocene Advisors first reported a position in MDCO in Q4 2017 and held it in 2 quarters. The position peaked at $8.83M in Q3 2019. 284 funds tracked by Wall St. Rank hold MDCO as of Q4 2019.

  • Holocene Advisors reported no remaining Medicines Co position as of Q4 2019 after selling out during the quarter.
  • Holocene Advisors sold 176,515 Medicines Co shares in Q4 2019, an estimated $8.83M.
  • Holocene Advisors first reported a position in Medicines Co in Q4 2017 and held it in 2 quarters.
  • Holocene Advisors's Medicines Co position peaked at $8.83M in Q3 2019.
  • 284 funds tracked by Wall St. Rank held Medicines Co as of Q4 2019.

Based on Holocene Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.